Bayer Pharmaceuticals began construction of a $59 million production and supply plant to expand its existing site in Beijing with the aim of increasing production capacity and accelerating the implementation of digital solutions.
New production lines, which are expected to become operational by the end of 2022, will increase the annual output of the Beijing site by about 40 percent —reinforcing the site's position among the most advanced production sites in the drugmaker's global network.
The expansion project taps into a nationwide public health initiative, "Healthy China 2030," which includes a heavy focus on managing chronic disease in China. Bayer established its first plant in the Beijing Economic-Technological Development Area in 1995 and since has been producing a range of treatments for diabetes, hypertension and other cardiovascular diseases.
The expansion project covers production area and related technical area. It includes new high-speed production lines in combination with a sophisticated logistics system.
Read the China Daily coverage
